Work

Beyond weight loss: Effect of GLP-1 receptor agonist therapy on the urological health

Year: 2026

Type: article

Abstract: Background: Glucagon-like-peptide-1 receptor agonists (GLP-1-RA) are increasingly prescribed medications with well-documented gastrointestinal adverse effects. Urologic adverse effects remain poorly characterized. Case presentation: A 40-year-old male developed reproducible urinary frequency, penile pruritus, dysuria, pelvic/perineal pain, and sexual dysfunction 3-4 weeks after initiating tirzepatide therapy. Comprehensive infectious evaluation remained negative. Symptoms improved 4 days after discontinuing tirzepatide with complete resolution in 10 days and no recurrence two weeks after last injection. Conclusion: This case describes novel urologic adverse effects associated with GLP-1-RA therapy. Clinicians should consider medication-related etiologies in patients with atypical urogenital symptoms with negative infectious workup during GLP-1-RA use.

Source: Urology Case Reports

DOI: 10.1016/j.eucr.2026.103368

Authors: Arisha Tariq, Adrian Garza Gangemi, Jaime Herrera Caceres

Institutions: Pennsylvania State University, Penn State Milton S. Hershey Medical Center

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,160